CTMX (STOCKS)
CytomX Therapeutics, Inc.
$3.100000
+0.090000 (+2.99%)
Prev close: $3.010000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sean A. McCarthy
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $661.82M
- Employees
- 121
- P/E (TTM)
- -8.36
- P/B (TTM)
- 2.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.10 | $-0.12 | +0.0232 | +18.83% |
|
Dec 2025 (Q4)
|
$-0.22 | $-0.10 | -0.1245 | -130.37% |
|
Sep 2025 (Q3)
|
$-0.09 | $-0.05 | -0.0384 | -74.42% |
|
Jun 2025 (Q2)
|
$0.00 | $-0.08 | +0.0772 | +98.72% |
Financial Statements
| Revenues | $35.54M |
| Benefits Costs and Expenses | $94.45M |
| Costs And Expenses | $94.45M |
| Operating Expenses | $100.20M |
| Research and Development | $69.10M |
| Other Operating Expenses | $31.10M |
| Operating Income/Loss | -$64.66M |
| Income/Loss From Continuing Operations After Tax | -$59.14M |
| Income/Loss From Continuing Operations Before Tax | -$58.91M |
| Income Tax Expense/Benefit | $234.00K |
| Net Income/Loss | -$59.14M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$59.14M |
| Net Income/Loss Available To Common Stockholders, Basic | -$62.14M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $3.00M |
| Preferred Stock Dividends And Other Adjustments | $3.00M |
| Basic Average Shares | 481,936,344 |
| Diluted Average Shares | 480,428,858 |
| Assets | $359.36M |
| Current Assets | $353.10M |
| Noncurrent Assets | $6.26M |
| Fixed Assets | $1.09M |
| Other Non-current Assets | $5.17M |
| Liabilities | $39.41M |
| Current Liabilities | $34.02M |
| Accounts Payable | $1.37M |
| Wages | $3.90M |
| Other Current Liabilities | $28.75M |
| Noncurrent Liabilities | $5.39M |
| Equity | $319.94M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $319.94M |
| Liabilities And Equity | $359.36M |
| Net Cash Flow From Operating Activities | -$80.09M |
| Net Cash Flow From Operating Activities, Continuing | -$80.09M |
| Net Cash Flow From Investing Activities | -$283.12M |
| Net Cash Flow From Investing Activities, Continuing | -$283.12M |
| Net Cash Flow From Financing Activities | $354.49M |
| Net Cash Flow From Financing Activities, Continuing | $354.49M |
| Net Cash Flow | -$8.72M |
| Net Cash Flow, Continuing | -$8.72M |
| Comprehensive Income/Loss | -$59.07M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$59.04M |
| Other Comprehensive Income/Loss | -$14.16M |